Related Experiment Video

Updated: May 14, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

The impact of IGF-I gene polymorphisms on coronary artery disease susceptibility

Hsiu-Ling Lin1, Kwo-Chang Ueng, Hsiang-Ling Wang

  • 1Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.

Journal of Clinical Laboratory Analysis
|February 21, 2013
PubMed
Abstract

Insights

Genetic variations in insulin-like growth factor (IGF) genes are linked to coronary artery disease (CAD) risk. Specific IGF-I gene polymorphisms, IGF-I +1770 and IGF-I +6093, are associated with increased CAD risk and related complications like high blood pressure and congestive heart failure.

Area of Science:

  • Genetics
  • Cardiology
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) is a leading cause of death in Taiwan.
  • The insulin-like growth factor (IGF) system, including IGF-I and IGFBP-3, is implicated as a potential risk factor for CAD.
  • This study explores the association between specific genetic polymorphisms in the IGF system and CAD risk in the Taiwanese population.

Purpose of the Study:

  • To investigate the relationship between IGF-I +1770, IGF-I +6093, and IGFBP-3 -202 genetic polymorphisms and the risk of developing CAD.
  • To determine if these polymorphisms are associated with clinical outcomes in patients with CAD, such as blood pressure and congestive heart failure.

Main Methods:

  • A case-control study involving 581 participants (390 non-CAD controls, 191 CAD patients).
  • DNA was isolated and analyzed using real-time polymerase chain reaction to identify specific genetic polymorphisms.
  • Statistical analysis was performed to evaluate the association between polymorphisms and CAD risk and outcomes.

Main Results:

  • A significant association was found between the IGF-I +1770 gene polymorphism and an increased risk of CAD.
  • CAD patients with mutant alleles in IGF-I +1770 exhibited significantly higher systolic and diastolic blood pressure.
  • CAD patients with mutant alleles in IGF-I +6093 showed a 1.695-fold increased risk of congestive heart failure.

Conclusions:

  • The IGF-I +1770 gene polymorphism is associated with an elevated risk of CAD.
  • The IGF-I +1770 and +6093 polymorphisms may influence CAD development and progression through their effects on blood pressure and heart failure risk.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...